W
WAVEMAN · COMPANY
CYAN · Cyanotech Corp
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

CYAN

CYANOTECH CORP
PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0000768408
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+5.0%
XBRL, annual
NET MARGIN
-13.2%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+5.0% year over year
more than 54% of Pharma & Biotech
MARGIN
-13.2% net margin
more than 54% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
0.1% of shares outstanding short · 1.3 days to cover · settled 2026-07-31
below 90% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +75.0%
+75.0%12M
-7%+30%+67%+104%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
Every figure on this page is a federal filing, dated the day it became public — so you can test what was knowable, not what is known now.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for CYANOTECH CORP in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
DAVIS MICHAEL A /
Director
BUY
2024-10-01
5,000.0
$3.8K
DAVIS MICHAEL A /
Director
BUY
2024-09-30
5,000.0
$3.8K
DAVIS MICHAEL A /
Director
BUY
2024-09-27
5,000.0
$3.9K
DAVIS MICHAEL A /
Director
BUY
2024-09-26
5,000.0
$3.9K
DAVIS MICHAEL A /
Director
BUY
2024-09-25
5,000.0
$3.9K
78 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 73 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$315.2K
$267.3K
$201.6K
-89%
2023
$322.8K
$248.6K
$160.5K
-91%
2022
$376.8K
$438.0K
$160.9K
-73%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-032024-032023-032022-03
REVENUE$24.2M$23.1M$23.2M$36.0M
GROSS PROFIT$6.9M$5.9M$7.3M$13.6M
OPERATING INCOME$-2.5M$-4.6M$-2.9M$2.6M
NET INCOME$-3.2M$-5.3M$-3.4M$2.2M
EPS (DILUTED)-0.81-0.550.35
OPERATING CASH FLOW$-1.2M$-455.0K$-2.1M$2.4M
CASH$257.0K$707.0K$974.0K$2.6M
LONG-TERM DEBT$1.0M$1.0M$1.0M$4.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →